Life Science Success
Alex Zhavoronkov - CEO Insilico Medicine
Jun 10, 2023
Alex Zhavoronkov, CEO of Insilico Medicine, discusses the progress and capabilities of Insilico Medicine, an AI-powered drug discovery company. They emphasize the need for validation and optimizing success probability in using AI tools in drug discovery. They also explore the evolution of Insilico Medicine into a software company and the importance of partnering with pharmaceutical companies. Furthermore, they discuss how In Silico aligns with the theme of science and innovation and their commitment to maximizing life through advancements in AI and future technologies.
24:41
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Insilico Medicine utilizes a platform incorporating biology engines, generative AI, and clinical trial outcome predictions in their AI-powered drug discovery process.
- Partnering with pharmaceutical companies at the preclinical candidate stage is Insilico Medicine's main strategy, enabling optimal clinical trial designs and increasing the chances of success.
Deep dives
Overview of the Conference and Bio2023
The speaker discusses the Bio2023 conference and highlights its energetic atmosphere and vibrant community. They mention the global participation and active partnerships, collaborations, and knowledge sharing that take place at the conference.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
